Lipella Pharmaceuticals

29 articles about Lipella Pharmaceuticals

• Lipella Pharmaceuticals Expands its Advisory Board

  4/17/2024

  Lipella Pharmaceuticals Inc. today announced the expansion of its Scientific Advisory Board to include oncology expertise.

• Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024

  4/5/2024

  Lipella Pharmaceuticals Inc. (NASDAQ: LIPO) (“Lipella,” “our”, “us” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that its abstract has been accepted for the 2024 American Society of Clinical Oncology (ASCO) meeting on May 31 through June 4 in Chicago, Illinois.

• Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

  4/3/2024

  Lipella Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has granted a Type C meeting request to discuss the company’s proposed Phase-2b clinical trial design for the evaluation of LP-10.

• PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease

  3/7/2024

  Lipella Pharmaceuticals was recently granted Orphan Drug Designation by the FDA for LP-410, its drug candidate for oral Graft-versus-Host Disease and previously received Orphan Drug Designation for LP-10 in 2023.

• Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

  3/5/2024

  Lipella Pharmaceuticals Inc. announces that the U.S. Food and Drug Administration has approved an Investigational New Drug application for clinical testing of LP-410 in the treatment of oral Graft-Versus-Host Disease.

• Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

  2/20/2024

  Lipella Pharmaceuticals Inc. announced today that Chief Medical Officer Dr. Michael Chancellor will present at the PropThink Digital Investor Conference’s key opinion leader (KOL) discussion on Friday, February 23, 2024, at 2 PM ET.

• Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished

  12/20/2023

  Lipella Pharmaceuticals Inc., (Nasdaq: LIPO) ("Lipella," "our," "us" or the "Company"), a pioneering, clinical-stage pharmaceutical company, celebrates its first anniversary as a publicly traded entity.

• FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

  11/10/2023

  Lipella Pharmaceuticals Inc. announced today that it has been granted "Orphan Drug Designation" from the U.S. Food and Drug Administration (FDA) for its drug candidate, LP-310, which has been designed for the treatment of oral Graft-versus-Host Disease (GvHD). 

• Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  10/25/2023

  Lipella Pharmaceuticals Inc. announced the closing of its previously announced private placement transaction, priced at-the-market under Nasdaq rules, for the purchase and sale of pre-funded warrants to purchase up to an aggregate of 1,315,790 shares and warrants to purchase up to an aggregate of 1,315,790 shares.

• Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  10/24/2023

  Lipella Pharmaceuticals Inc. announced the entry, on October 23, 2023, into definitive agreements for the purchase and sale, in a private placement transaction priced at-the-market under Nasdaq rules, of pre-funded warrants to purchase up to an aggregate of 1,315,790 shares and warrants to purchase up to an aggregate of 1,315,790 shares.

• Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

  10/20/2023

  Lipella Pharmaceuticals Inc. today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with no effective treatment.

• Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

  9/21/2023

  Lipella Pharmaceuticals Inc. today announces that the results of its successful Phase 2a clinical trial have been the published in the peer-reviewed Journal of Urology and Nephrology.

• Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

  5/15/2023

  Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provides a corporate update and announces its first quarter 2023 financial results.

• Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting

  5/1/2023

  Lipella Pharmaceuticals Inc. today announced that it has delivered a late-breaking presentation at the annual meeting of the American Urological Association (AUA) Annual Meeting in Chicago on April 30, 2023.

• Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

  4/17/2023

  Lipella Pharmaceuticals has entered into a manufacturing collaboration agreement with Cook MyoSite, Inc.

• Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent

  4/5/2023

  Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces it has dosed the first patient in its human clinical study of a novel bladder MRI contrast agent.

• Lipella Provides Business Update and Reports 2022 Financial Results

  3/31/2023

  Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provided a business update and reported financial results for the year ended December 31, 2022.

• Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association

  3/16/2023

  Lipella Pharmaceuticals Inc. today announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.

• Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board

  3/1/2023

  Lipella Pharmaceuticals Inc. today announced the creation of a Scientific Advisory Board in oral health.  

• Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10

  1/11/2023

  Lipella Pharmaceuticals Inc. today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments.